Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Olmesartan French Delisting Delayed, But Still Big Hit For Daiichi Sankyo

Executive Summary

The antihypertensive olmesartan is to lose its reimbursement status in France next year, on the grounds that its efficacy had been shown to be less convincing that that of other angiotensin receptor blockers.



Related Companies